On Sunday, February 28, 2021, NIAC Los Angeles hosted a COVID Vaccine Town Hall in Persian, open to members across the country. The purpose of this town hall was to provide accurate and up-to-date information in Farsi about the COVID vaccine.
We enjoyed an engaging discussion between esteemed panelists Dr. Farin Kamangar and Dr. Javad Aman, moderated by Dr. Kamran Tabaddor. This town hall shared important information regarding the latest research, common myths, and possible side effects of the COVID vaccine. Our panelists also answered questions from the audience about the different types of vaccines, the effect of the vaccines on people with pre-existing conditions, and the benefits of receiving the COVID vaccine.
Missed the event? You can watch the recording here!
Below you’ll find a list of resources that were mentioned at the town hall. Please stay healthy and stay safe!
- “Plan Your Vaccine”: https://www.nbcnews.com/specials/plan-your-vaccine/
- “New vaccines may not be right for some cancer patients; solid sewage beats wastewater for tracking virus”: https://www.reuters.com/article/health-coronavirus-science-int/new-vaccines-may-not-be-right-for-some-cancer-patients-solid-sewage-beats-wastewater-for-tracking-virus-idUSKBN28J2ZN
- “COVID-19 Vaccine & Patients with Cancer”: https://www.asco.org/asco-coronavirus-resources/covid-19-patient-care-information/covid-19-vaccine-patients-cancer
Javad Aman, Ph.D., has over 30 years of experience in the fields of immunology, microbiology, and vaccine development. A highly accomplished scientist, Dr. Aman has published over 100 scientific articles, including many in highly prestigious journals, such as Cell, Science, and Proceeding of the National Academy of Sciences.
Dr. Aman has made important discoveries, such as the receptor for human interleukin-13 as well as small molecule inhibitors and monoclonal antibodies for Ebola and Marburg viruses. In 2007, he founded the research-based company Integrated Biotherapeutics (IBT), where he and his staff develop vaccines and antibody therapeutics for emerging infectious diseases. The company has thus far received nearly $80 million of research funding from the US government and prestigious funding agencies.
Farin Kamangar, MD, Ph.D., is a physician-scientist with expertise in the field of epidemiology. Dr. Kamangar is currently a University Distinguished Professor and Associate Dean for Research at Morgan State University, Baltimore.
Dr. Kamangar is an accomplished scientist who has authored over 200 publications, including papers in the highly prestigious medical journals, such as The Lancet, the Lancet Oncology, and British Medical Journal (BMJ). He has been the principal investigator or co-principal investigator of nearly $60 million in grant funding and works closely with scientists from the US National Institutes of Health, World Health Organization, and Tehran University. He has received over 20 awards and honors for his research, teaching, and service.Back to top